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Abstract Hypoxemia has been recognized as a risk
factor for bone loss. The aim of the present study is to
investigate the relationship of bone mass and density
measures with anemia and hemoglobin levels in a large
sample of older community-dwelling persons. The
study is based on data from 950 participants enrolled
in the ‘‘Invecchiare in Chianti’’ (Aging in the Chianti
area, InCHIANTI) study. All the analyses were per-
formed considering continuous hemoglobin levels as
well as the dichotomous anemia variable (deﬁned
according to WHO criteria as hemoglobin <12 g/dl in
women and <13 g/dl in men). A peripheral quanti-
tative computerized tomography (pQCT) scan of the
right calf was performed in all participants to evaluate
total bone density, trabecular bone density, cortical
bone density, and the ratio between cortical and total
bone area. Linear regression analyses were used to
assess the multivariate relationship of pQCT bone
measures with anemia and hemoglobin levels after
adjustment for demographics, chronic conditions,
muscle strength and biological variables. Participants
were 75.0 (SD 6.9) years old. In our sample, 101
participants (10.6%) were anemic. In women, coeﬃ-
cients from adjusted linear regression analyses evalu-
ating the association between pQCT bone measures
(per SD increase) and hemoglobin levels/anemia
showed signiﬁcant associations of anemia with total
bone density (b=)0.335, SE=0.163; P=0.04) and
cortical bone density (b=)0.428, SE=0.160;
P=0.008). Relationships with borderline signiﬁcance
were found for the associations of anemia with tra-
becular bone density and the ratio between cortical
and total bone area. Signiﬁcant associations were
found between hemoglobin levels and trabecular bone
density (b=0.112, SE=0.049; P=0.02), total bone
density (b=0.101, SE=0.046; P=0.03), cortical
bone density (b=0.100, SE=0.046; P=0.03) and the
ratio between cortical bone and total area (b=0.092,
SE=0.045; P=0.04). In men, signiﬁcant associations
were found for hemoglobin levels with total bone
density (b=0.076, SE=0.036; P=0.03) and cortical
bone density (b=0.095, SE=0.41; P=0.02). A bor-
derline signiﬁcance was reported for the association
between anemia and cortical bone density. We con-
cluded that anemia and low hemoglobin levels are
negatively and independently associated with bone
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mass and density. The bone loss associated with
hemoglobin levels mainly occurs in the cortical bone.
Women with lower hemoglobin levels demonstrate a
higher bone loss than male counterparts.
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Introduction
Anemia, a common condition that aﬀects approximately
13% of persons aged 70 years or older [1], has been
deﬁned by the World Health Organization (WHO) [2] as
a hemoglobin level lower than 12 g/dl for women and
13 g/dl for men. The reported decrease in hemoglobin
concentrations that occur during the aging process
might be due to a lower erythropoietin secretion [3] or a
reduced hematopoietic reserve [4]. However, a strong
association between anemia and comorbidity has also
been shown, which has led to the recommendation that
hemoglobin levels below normal ranges should always
be investigated in clinical practice [5]. Late-life anemia
has been associated with clinical outcomes such as
mortality [5], disability [6, 7, 8], loss of physical perfor-
mance [9] and poor quality of life [10]. Moreover, ane-
mia is so frequently found in frail older persons that it
has been deﬁned as a biological marker of the frailty
syndrome [11].
Lower levels of bone mass with age have been
widely documented [12]. This decline, more evident in
women than in men [13], is responsible for a weaker
resistance of the bone to external forces [12, 14].
Osteoporosis, characterized by bone mass reduction
and by a higher risk of consequent fractures, is a
common condition in older persons, and its prevalence
increases with age [12, 15]. The consequent increased
risk of fractures is an important issue in geriatrics, gi-
ven the associated clinical and socio-economic burden
[8, 12, 16, 17].
Several reports in speciﬁc populations (such as in
thalassemia and hemodialysis patients) are available in
the literature and suggest a direct relationship of ane-
mia and hemoglobin levels with bone density [16, 18,
19, 20, 21]. Moreover, hypoxemia has been recognized
as a risk factor for bone loss [20]. Nevertheless, this
topic has not yet been deeply studied in the general
older population. Furthermore, to our knowledge,
studies that have analyzed the association between
hemoglobin levels and bone density have not distin-
guished between the trabecular and the cortical bone,
despite reports of diﬀerent changes that occur with age
in these two components [13]. The aim of the present
study is to investigate the relationship of bone mass
and density measures, assessed by peripheral quantita-
tive computerized tomography (pQCT), with anemia
and hemoglobin levels in a large sample of older
community-dwelling persons.
Methods
The study is based on data from the ‘‘Invecchiare in
Chianti’’ (Aging in the Chianti area, InCHIANTI)
study. The InCHIANTI study is a prospective popula-
tion-based study of older people, designed by the Lab-
oratory of Clinical Epidemiology of the Italian National
Research Council of Aging (INRCA, Florence, Italy).
The InCHIANTI study population includes 1,156
participants aged 65 to 102 years, randomly selected
from residents in two towns of the Chianti geographic
area (Greve in Chianti and Bagno a Ripoli, Tuscany,
Italy). The data collection started in September 1998 and
was completed in March 2000. A detailed description of
the sampling procedure and data collection method has
been previously published [22]. The Italian National
Research Council on Aging Ethical Committee ratiﬁed
the entire study protocol.
The present analyses were performed on 950 partici-
pants, after exclusion of those subjects in whom hemo-
globin levels and pQCT measures were not assessed
(n=206). The only sociodemographic characteristic in
which excluded participants diﬀered from those consid-
ered for the present analyses was older age (80.3 vs 75.0
years, P<0.001).
Anemia
Blood samples were obtained from participants after a
12-h fast. Participants had also been sedentary in the
sitting or supine position for at least 15 min before the
blood draw. Hemoglobin levels were analyzed with the
hematology automated Autoanalyzer DASIT SE 9000
(Sysmex Corporation, Kobe, Japan). For the study we
used: (1) a dichotomous anemia indicator, deﬁned by the
WHO criteria [2] as hemoglobin levels lower than 12 g/
dl for women and 13 g/dl for men; (2) a continuous
hemoglobin level variable; (3) a categorical variable that
distinguished hemoglobin levels into: (a) anemia as de-
ﬁned by the WHO criteria [2]; (b) Hemoglobin levels
between 0 and 0.9 g/dl above the anemia cut-oﬀ point;
(c) Hemoglobin levels between 1 and 1.9 g/dl above the
anemia cut-oﬀ point; (d) Hemoglobin levels ‡2 g/dl
above the anemia cut-oﬀ point.
pQCT measures
We performed a right-leg pQCT scan on all participants
with a recent generation device (XCT-2000, Stratec,
Pforzheim, Germany) to evaluate several bone mass and
density parameters. Data presented here are derived
from standard 2.1 mm-thick transverse scans obtained
at 4% (where trabecular bone is most abundant) and
38% (where the cortex is thick enough to allow the
accurate measurement of cortical bone density) of the
tibial length, starting from the tibio-tarsal joint.
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The bone density (in milligrams per centimeter cubed)
and the bone area (in millimeters squared) were calcu-
lated with BonAlyse software, version 1.3 (BonAlyse,
Jyva¨skyla¨, Finland). Diﬀerent tissues in the analysis
were separated according to diﬀerent density thresholds.
Areas with density values above 710 mg/cm3 were con-
sidered as ‘‘cortical bone’’, while areas with density
values between 180 and 710 mg/cm3 were considered as
‘‘trabecular bone’’ [13, 23]. The precision error of the
XCT-2000 is below 1% for volumetric trabecular and
cortical density and for cortical bone area [13, 23, 24].
The following pQCT bone measures were considered for
the present analyses: total bone density (4%); trabecular
bone density (4%); total bone density (38%); cortical
bone density (38%); ratio between cortical and total
bone area (38%).
Covariates
Covariates included sociodemographic variables [age,
gender, study site, smoking habit, Mini Mental State
Examination (MMSE) score, education]; height; weight;
comorbidity (adjudicated diagnoses of hypertension,
angina, myocardial infarction, stroke, cancer, diabetes,
congestive heart failure, chronic obstructive pulmonary
disease); physical activity (deﬁned as moderate-to-high-
intensity exercise performed for at least 1–2 h per week
or light-intensity exercise performed for more than 4 h
per week), as well as biological parameters [serum
albumin, creatinine, calcium, 25(OH)-vitamin D, and
parathyroid hormone (PTH)]. Adjudicated disease
diagnoses were based on self-reported history, clinical
assessment by the study geriatrician, and medication
use. Serum albumin (as a percentage) was detected by
electrophoresis (Hydragel 7 Protein, Sebia, France;
mean inter-assay coeﬃcient 0.8%), and its concentration
was calculated from serum total proteins (Roche Diag-
nostics, inter-assay coeﬃcient of variation was lower
than 1%). Serum creatinine was detected by a standard
creatinine Jaﬀe method (Roche Diagnostics, Mannheim,
Germany); inter-assay coeﬃcient of variation was less
than 2.5%. The serum calcium level was determined by a
colorimetric assay.
The inter-assay coeﬃcient of variation and the ana-
lytical sensitivity were 1.5% and 0.2 mg/dl, respectively.
A proportion (two 0.5 ml aliquots) of serum sample was
frozen and stored at –80C for 25(OH)-vitamin D and
PTH determination. Serum levels of 25(OH)-vitamin D
were measured by RIA (DiaSorin, Stillwater, Minn.,
USA), after extraction of the samples with acetonitrile.
Intra-assay and inter-assay coeﬃcients of variation were
8.1% and 10.2%, respectively. Serum intact PTH levels
were measured with a two-site immunoradiometric assay
(N-tact PTHSP, DiaSorin) kit. The assay uses two
aﬃnity-puriﬁed polyclonal antibodies, one speciﬁc for
the amino-terminal 1–34 portion of the PTH molecule,
and the second speciﬁc for the 39–84 sequence of the
hormone. The assay sensitivity was 1.2 ng/l. Intra-assay
and inter-assay coeﬃcients of variation were <3.0%
and 5.5%, respectively.
Ankle extension strength: The ankle extension
strength, measured with a hand-held dynamometer
(Nicholas Muscle Tester, Sammon Preston, Chicago,
USA), was used in the study as a potential confounder
of the association between hemoglobin levels and the
pQCT bone measures. Participants, lying in lateral de-
cubitus (opposite to the examined limb) with the hip and
the knee extended and the ankle in a neutral position,
were asked to perform the task twice with the right foot.
The average of the results obtained was used for the
analyses. This measurement has been used as a muscular
strength parameter of the lower limb [25]. In our sample,
this measure is highly correlated with other performance
measures, such as hand grip strength or knee extension
strength (Spearman correlation r=0.647 and r=0.790,
respectively; both P<0.001), which have been shown to
predict mortality and disability in the elderly [26, 27].
Interleukin-6 (IL-6): IL-6 was separately considered
as an additional potential explanatory covariate in the
adjusted models to determine whether inﬂammation was
able to explain the association between hemoglobin
levels and pQCT bone measures. In fact, it has been
suggested that IL-6, a multifunctional cytokine and a
marker of the geriatric syndrome of frailty [11], might be
involved in bone turnover [11, 28, 29]. IL-6 was quan-
tiﬁed with immunoassay kits (BioSource Cytoscreen
human IL-6 UltraSensitive kit). The minimum detect-
able concentration was 0.10 pg/ml. The inter-assay
coeﬃcient of variation was 7%. All assays were done in
duplicate and repeated if the second measurement was
more than 10% greater or less than the ﬁrst. The average
of the two measurements was used in the analyses. Be-
cause of the non-normal distribution of serum IL-6, its
log values were used in the analyses.
Statistical analyses
Diﬀerences in proportions and means of covariates
according to anemia status were assessed with chi-square
and ANOVA statistics, respectively. Median values with
the 25th-75th percentile ranges and P values based on
Mann–Whitney U statistics were reported for non-nor-
mally distributed variables. All variables found to be
diﬀerent, with a P value <0.10 in univariate analyses,
were used as adjustment covariates in subsequent mul-
tivariate analyses. Gender interactions were assessed by
the testing of the interaction term added to the adjusted
models as a covariate. We used linear regression ana-
lyses to identify regression coeﬃcients (with standard
error) in calf pQCT measures for continuous hemoglo-
bin levels as well as for the dichotomous anemia vari-
able. We performed analyses of covariance to assess
diﬀerences in adjusted means of bone measurements
according to hemoglobin levels.
A regression coeﬃcient (b) from a linear regression
model is a constant that represents the slope of the
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regression line between two variables (i.e., y= bone
density measure, x= hemoglobin). The regression line is
provided by the equation: y=bx+a, where a represent
the intercept of the regression line on the y axis. A po-
sitive regression coeﬃcient indicates a direct relation-
ship, a negative regression coeﬃcient indicates an
inverse relationship. The regression coeﬃcients reported
in the present paper provide the estimates of expected
changes in bone density measures (per SD increase) for
1 g/dl increments for hemoglobin levels and for the
diﬀerence between non-anemic vs anemic participants.
Results
The mean age of the sample population (n=950) was
75.0 (SD 6.9) years and the prevalence of women was
55.8%. A total of 101 (10.6%) subjects had anemia
according to the WHO criteria. The prevalence of ane-
mia was similar in women (10.6%) and men (10.7%).
Anemicmen andwomenwere older, had lower levels of
albumin, were more likely to have a history of stroke and
reported worse results of muscular strength than did their
non-anemic counterparts (Table 1). Anemic women also
had higher levels of PTH than non-anemic women, while
anemicmenwere less educated,more likely to have gastric
ulcers and higher levels of creatinine and IL-6 than men
with normal levels of hemoglobin. No signiﬁcant diﬀer-
ences were found for physical activity levels according to
the presence of anemia in both men and women. The use
of some medications able to aﬀect bone mass parameters
(such as hormone replacement therapy, bisphosphonates,
or calcium supplements) was not included in the list of
potential confounders, given the extremely lowprevalence
found in our sample (hormone replacement therapy: no
participants; bisphosphonates: three participants, 0.3%;
calcium supplements: six participants, 0.6%; vitamin D
supplements: 12 participants, 1.3%).
Because of the signiﬁcant interactions between
hemoglobin levels and gender with total bone density
(P=0.04) and the ratio between cortical bone area and
total bone area (P=0.001), all the analyses were strati-
ﬁed for gender. Similar signiﬁcant interactions were also
found when we tested the interaction between the ane-
mia dichotomous variable and gender with pQCT bone
measures.
Table 1 Characteristics [mean ± SD, %, or median (interquartile range)] of the population, stratiﬁed for gender
Characteristic Women (n=530) Men (n=420)
No anemia Anemia P No anemia Anemia P
(n=474) (n=56) (n=375) (n=45)
Sociodemographic
Age (years) 74.9±6.7 81.7±7.6 <0.001 73.8±6.2 78.9±8.1 <0.001
Site (Bagno a Ripoli) 54.6 42.9 0.10 51.7 51.1 0.94
Height (cm) 153.1±6.8 150.0±7.9 0.003 165.8±7.2 161.8±8.7 0.001
Weight (kg) 65.5±11.4 58.1±10.5 <0.001 75.0±11.4 67.6±12.2 <0.001
Smoking 0.19 0.70
Never 81.2 91.1 29.6 26.7
Former 10.8 5.4 53.6 60.0
Current 8.0 3.6 16.8 13.3
Education (years) 4.8±2.8 4.3±3.4 0.26 6.4±3.7 4.8±2.9 0.006
Physical activitya 26.9 19.6 0.24 53.6 44.4 0.24
Comorbidity
Coronary heart disease 7.7 13.2 0.17 10.5 15.9 0.28
Congestive heart failure 6.8 7.1 0.91 4.8 11.1 0.08
Diabetes 9.5 3.6 0.14 12.0 11.1 0.86
Stroke 4.6 12.5 0.01 5.9 24.4 <0.001
Pulmonary disease 3.4 - 0.16 10.1 15.6 0.27
Hypertension 57.0 62.3 0.46 46.1 43.2 0.71
Gastric ulcer 2.7 5.4 0.28 5.1 31.1 <0.001
Cancer 7.7 7.5 0.97 4.0 9.1 0.13
Peripheral artery disease 8.2 8.9 0.86 8.0 11.1 0.48
Serum biological markers
Albumin (g/dl) 4.2±0.3 4.0±0.3 <0.001 4.3±0.3 4.1±0.4 <0.001
Creatinine (mg/dl) 0.9±0.2 0.9±0.5 0.01 1.0±0.2 1.1±0.4 <0.001
Calcium (mg/dl) 9.5±0.5 9.3±0.5 0.001 9.4±0.4 9.3±0.4 0.006
Parathyroid hormone (pmol/l)b 23.5 (16.0–33.1) 28.4 (17.8–39.7) 0.02 20.8 (15.5–27.7) 22.6 (13.5–30.5) 0.97
25(OH)-vitamin D (nmol/l)b 35.2 (24.0–51.0) 31.0 (21.7–40.9) 0.06 54.2 (35.9–74.6) 43.4 (29.7–76.4) 0.25
Interleukin-6 (pg/ml)b 1.3 (0.8–2.0) 1.5 (0.9–2.8) 0.20 1.5 (0.9–2.4) 2.1 (1.1–5.5) 0.005
Muscle strength
Ankle extension strength (kg) 24.4±10.1 15.8±11.8 <0.001 33.3±12.4 25.5±15.6 <0.001
aPercentage of participants that reported moderate-to-high intensity exercise performed for at least 1–2 h per week or light intensity
exercise performed for more than 4 h per week
bMedian (interquartile range)
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In univariate unadjusted analyses, a signiﬁcant diﬀer-
ence, according to anemia status, was reported for cortical
bone density for both genders (Table 2). Anemic women
were also more likely to present lower levels of total bone
density, trabecular bone density and a reduced ratio
between cortical bone area and total bone area.
Table 3 shows coeﬃcients (adjusted for age, site,
height, weight, education, congestive heart failure,
stroke, gastric ulcer, serum albumin, creatinine, calcium,
25(OH)-vitamin D, PTH, and ankle extension strength)
from linear regression analyses evaluating the associa-
tion between pQCT bone measures (per SD increase)
and hemoglobin levels/anemia. In women, signiﬁcant
associations were found between anemia, and total bone
density and cortical bone density. Borderline signiﬁ-
cances were found for the associations between anemia,
and trabecular bone density and the ratio between cor-
tical and total bone area. Signiﬁcant associations were
found between hemoglobin levels, and trabecular bone
density, total bone density, cortical bone density, and
the ratio between cortical bone and total area. In men, a
signiﬁcant association was found for the associations
between hemoglobin levels, and total bone density and
cortical bone density. A borderline signiﬁcance was re-
ported for the association between anemia and cortical
bone density.
In order to test whether IL-6, an inﬂammatory
cytokine, was able to explain part of the link between
Table 2 pQCT bone
measurements, according to
anemia status and gender, in
crude unadjusted analyses
Parameter No anemia Anemia P
Mean ± SD Mean ± SD
Women (n=530)
Scan performed at 4% of the tibial length
Total bone density (mg/cm3) 238.4±47.9 224.3±47.8 0.04
Trabecular bone density (mg/cm3) 199.3±59.4 178.9±76.3 0.02
Scan performed at 38% of the tibial length
Total bone density (mg/cm3) 856.6±98.7 780.8±108.7 <0.001
Cortical bone density (mg/cm3) 987.6±70.6 934.5±95.5 <0.001
Cortical bone area/total bone area 0.74±0.10 0.66±0.12 <0.001
Men (n=420)
Scan performed at 4% of the tibial length
Total bone density (mg/cm3) 282.0±51.0 267.7±49.9 0.08
Trabecular bone density (mg/cm3) 220.3±53.3 211.0±59.1 0.29
Scan performed at 38% of the tibial length
Total bone density (mg/cm3) 914.7±73.2 893.6±87.7 0.07
Cortical bone density (mg/cm3) 1,018.9±61.8 992.5±86.9 0.01
Cortical bone area/total bone area 0.81±0.06 0.81±0.06 0.99
Table 3 Adjusteda regression coeﬃcients (with SE) for the association of anemia and hemoglobin levels with pQCT bone measuresb
Parameter Anemia Hemoglobin levels
Regression coeﬃcient (SE) P Regression coeﬃcient (SE) P
Women (n=530)
Scan performed at 4% of the tibial length
Total bone density (mg/cm3) )0.109 (0.147) 0.45 0.074 (0.041) 0.07
Trabecular bone density (mg/cm3) )0.304 (0.173) 0.08 0.112 (0.049) 0.02
Scan performed at 38% of the tibial length
Total bone density (mg/cm3) )0.335 (0.163) 0.04 0.101 (0.046) 0.03
Cortical bone density (mg/cm3) )0.428 (0.160) 0.008 0.100 (0.046) 0.03
Cortical bone area / Total bone area )0.271 (0.160) 0.09 0.092 (0.045) 0.04
Men (n=420)
Scan performed at 4% of the tibial length
Total bone density (mg/cm3) )0.112 (0.176) 0.53 0.043 (0.042) 0.30
Trabecular bone density (mg/cm3) )0.116 (0.158) 0.94 0.010 (0.037) 0.79
Scan performed at 38% of the tibial length
Total bone density (mg/cm3) )0.152 (0.149) 0.31 0.076 (0.036) 0.03
Cortical bone density (mg/cm3) )0.319 (0.170) 0.06 0.095 (0.041) 0.02
Cortical bone area / Total bone area 0.074 (0.128) 0.56 0.028 (0.031) 0.36
aAdjusted for age, site, height, weight, education, congestive heart
failure, stroke, gastric ulcer, serum albumin, creatinine, calcium,
parathyroid hormone (logarithmic value), 25(OH)-vitamin D
(logarithmic value), ankle extension strength
bPer SD increase. SDs: total bone density (4%) 53.854 mg/cm3;
trabecular bone density (4%) 59.353 mg/cm3; total bone density
(38%) 96.561 mg/cm3; cortical bone density (38%) 72.982 mg/cm3;
cortical bone area/total bone area (38%) 0.095
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hemoglobin and bone density, we entered IL-6 in the
adjusted models. No signiﬁcant discrepancy from pre-
vious ﬁndings was reported. In fact, when we added the
inﬂammatory marker to the models, it did not modify
the associations of anemia with trabecular bone density
(b=)0.304, SE=0.174; P=0.08), total bone density
(scan performed at the 38% tibial length; b=)0.336,
SE=0.164; P=0.04), cortical bone density (b=)0.428,
SE=0.162; P=0.008) and the ratio between cortical and
total bone area (b=)0.268, SE=0.161; P=0.09) and of
hemoglobin levels with trabecular bone density
(b=0.112, SE=0.049; P=0.02), total bone density (scan
performed at the 4% tibial length; b=0.076, SE=0.042;
P=0.07; scan performed at the 38% tibial length;
b=0.101, SE=0.049; P=0.03), cortical bone density
(b=0.099, SE=0.046; P=0.03) and the ratio between
cortical and total bone area (b=0.092, SE=0.046;
P=0.04) previously found in women.
Similarly, in men, the reported signiﬁcant association
between anemia and cortical bone density was not
inﬂuenced by IL-6 levels (b=)0.317, SE=0.170;
P=0.06), or the associations of hemoglobin levels with
total bone density (scan performed at the 38% tibial
length: b=0.074, SE=0.036; P=0.04) and cortical bone
density (b=0.095, SE=0.041; p=0.02).
Finally, we performed adjusted analyses of covari-
ance to evaluate the relationships of hemoglobin levels
above and below the anemia cut-oﬀ points in men and
women with pQCT bone measures (Fig. 1). A signiﬁcant
diﬀerence in cortical bone density was found between
men with hemoglobin levels ‡2 g/dl above the anemia
cut-oﬀ point and anemic men (1,026.3 mg/cm3 vs
992.3 mg/cm3; P=0.01). In women, signiﬁcant diﬀer-
ences according to hemoglobin levels were found for
trabecular bone density (anemia: 180.8 mg/cm3; hemo-
globin ‡2 g/dl above anemia cut-oﬀ point: 207.7 mg/
cm3; P=0.02), total bone density (anemia: 820.6 mg/
cm3; hemoglobin 1–1.9 g/dl above anemia cut-oﬀ value:
859.7 mg/cm3, P=0.02; hemoglobin ‡2 g/dl above ane-
mia cut-oﬀ point: 860.0 mg/cm3; P=0.03), cortical bone
density (anemia: 955.4 mg/cm3; hemoglobin <1 g/dl
above anemia cut-oﬀ value: 985.0 mg/cm3, P=0.02;
hemoglobin 1–1.9 g/dl above anemia cut-oﬀ: 987.0 mg/
cm3, P=0.01; hemoglobin ‡2 g/dl above anemia cut-oﬀ:
988.9 mg/cm3; P=0.01), and cortical/total bone area
ratio (anemia: 0.713; hemoglobin 1–1.9 g/dl above ane-
mia cut-oﬀ point: 0.745, P=0.05; hemoglobin ‡2 g/dl
above anemia cut-oﬀ: 0.746; P=0.05).
Discussion
To our knowledge ours is the ﬁrst study exploring the
relationship between hemoglobin levels and anemia and
pQCT bone measures in a representative sample of the
older population. We measured separately the cortical
and trabecular components of the bone. Participants
with lower levels of hemoglobin or with anemia had
lower levels of bone density, especially in the cortical
bone. Such associations were more evident in women
than in men.
Several mechanisms that lead to bone loss during the
aging-process have been suggested. Hormone-related
mechanisms have been documented to be responsible for
the decline of bone density in postmenopausal women
[30, 31, 32] as well as in older men [19, 30, 33]. Nutri-
tional factors may also contribute to the bone loss [12].
Moreover, several studies have directly or indirectly
suggested an association of hemoglobin levels with bone
density [16, 18, 19, 21]. However, to our knowledge, this
issue has never been speciﬁcally evaluated in the older
general population. In fact, current evidence is extremely
limited and derives mainly from special populations,
such as thalassemic patients [18, 21, 34].
An explanation for the relationship of anemia and
hemoglobin levels with bone density might be provided
by a study conducted by Fujimoto et al. [20], in which,
by combining results from animal and human models,
they suggested that hypoxemia can aﬀect mineral density
and might be a risk factor for bone loss. In fact, the
authors showed that patients with low PaO2 presented a
decreased bone mineral density. Furthermore, to exclude
the hypothesis that limited exercise was inﬂuencing their
results, they conducted an animal experiment and
showed that a signiﬁcantly lower bone density was
found in hypoxemic rats than in normoxemic rats.
During the aging process a reduction in bone mass
has been well documented [12]. The age-related rate of
bone loss is higher in women than in men [35] and
speciﬁcally aﬀects cortical and total bone density. The
age-related reduction of trabecular bone density seems
to be similar in men and women [13]. Even if limited by
the cross-sectional design of the study, our results are
substantially in agreement with those previous ﬁndings.
We have reported a stronger association of hemoglobin
levels with the cortical bone. In fact, we have found
signiﬁcant diﬀerences in cortical bone density (and cor-
tical bone area only in women) according to hemoglobin
levels. It has been demonstrated that age-related bone
remodeling and bone loss occur mainly in the cortical
bone that becomes ‘‘trabecularized’’ due to an increased
intracortical porosity, preferentially occurring in cortical
regions adjacent to the marrow cavity [30, 36, 37]. This
might provide an explanation for the particularly strong
association between hemoglobin levels and bone density
in that site. In our analyses we also reported a small but
signiﬁcant diﬀerence in trabecular bone density between
women with anemia and those with high hemoglobin
levels.
Several diseases characterized by low hemoglobin
levels or anemia have been associated with an increased
risk of bone loss or osteoporosis. In fact, it has been
demonstrated that pernicious anemia is associated with
a twofold to threefold increased risk of osteoporotic
fractures [38, 39]. A reduced bone density associated
with low hemoglobin levels has also been demonstrated
in hemodialysis patients [18]. Hens et al. [40] have shown
that, as chronic obstructive pulmonary disease becomes
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more severe, the prevalence of osteoporotic patients in-
creases. A direct correlation between bone density and
the severity of airway obstruction has also been found
[41]. Patients with thalassemia, a disease characterized
by anemia due to defective hemoglobin synthesis, often
present skeletal morbidity [42]. Even if a multifactorial
etiology has been shown to be responsible for these
pathological bone changes in thalassemia, low
hemoglobin levels and anemia have been recognized
among the risk factors [16, 18, 21]. Moreover, it has also
been demonstrated that the degree of bone loss is lower
in thalassemic patients receiving more blood transfu-
sions [34].
Recently, Kenny et al. [19] have shown a direct
association between testosterone levels and bone mass,
hypothesizing beneﬁcial eﬀects of testosterone supple-
Fig. 1 Adjusted mean of pQCT bone measurements according to
hemoglobin levels, stratiﬁed by gender; dark gray histograms
women; light gray histograms men. Adjusted for age, site, height,
weight, education, congestive heart failure, stroke, gastric ulcer,
serum albumin, creatinine, calcium, parathyroid hormone (loga-
rithmic value), 25(OH)-vitamin D (logarithmic value), ankle
extension strength. *P<0.05 compared to persons with anemia
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ment in men at risk of osteoporotic fractures. This
relationship might be partially explained by the known
association between anemia and low testosterone levels
[43, 44] and conﬁrmed by evidence that shows increased
levels of hemoglobin due to the use of androgenic ste-
roids [43].
It might be argued that our results might be caused
by an underlying chronic inﬂammatory status. In fact,
inﬂammation is independently associated with hemo-
globin levels [11] and it has been suggested to play an
important role in the bone resorption that occurs during
aging [11, 28, 29]. Therefore, we re-performed the
analyses, taking into account serum levels of IL-6 as a
covariate in our adjusted models. Results did not diﬀer
from previous ﬁndings, which suggested that the rela-
tionships of hemoglobin levels and anemia with pQCT
bone measures is independent of systemic inﬂammation.
The main limitation of the present study is its cross-
sectional design, which does not allow us to assess the
cause–eﬀect mechanism. Therefore, we cannot exclude
whether our ﬁndings are just the expression of a frailer
health status of participants or are, indeed, a causative
factor in the pathway leading from low hemoglobin
levels to bone density loss. Longitudinal studies are
needed to conﬁrm our ﬁndings. The InCHIANTI study
gives us the opportunity to adjust our analyses for many
health and disease-related characteristics that are dif-
ferent between anemic and non-anemic persons, but
there could be unmeasured confounders that we cannot
adjust for. Clinical trials are necessary to assess whether
treatments aimed at increasing hemoglobin levels are
also able to provide improved bone quality. In our
analyses we have not considered some medications able
to interfere, positively or negatively, with bone density,
such as hormone replacement therapy, calcium supple-
ments or bisphosphonates, because of their extremely
low use in our sample population. Finally, the bone
density measurements considered in the present study
are from tibial pQCT scans and, therefore, the general-
ization of our ﬁndings to the entire skeleton might be
diﬃcult.
In conclusion, our ﬁndings show that hemoglobin
levels and anemia are negatively and independently
associated with bone mass and density. The bone loss
associated with hemoglobin levels occurs mainly in the
cortical bone. Women with lower hemoglobin levels
might present a higher bone loss than male counterparts.
Further studies are needed to conﬁrm our ﬁndings and
to provide a better understanding of the pathophysio-
logic pathway that links anemia/hemoglobin levels with
bone density and mass measures.
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